SAMHD1 is a barrier to antimetabolite-based cancer therapies.
about
Nucleobase and Nucleoside Analogues: Resistance and Re-Sensitisation at the Level of Pharmacokinetics, Pharmacodynamics and MetabolismLow-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
P2860
SAMHD1 is a barrier to antimetabolite-based cancer therapies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
SAMHD1 is a barrier to antimetabolite-based cancer therapies.
@en
type
label
SAMHD1 is a barrier to antimetabolite-based cancer therapies.
@en
prefLabel
SAMHD1 is a barrier to antimetabolite-based cancer therapies.
@en
P2860
P50
P1476
SAMHD1 is a barrier to antimetabolite-based cancer therapies
@en
P2093
Sean G Rudd
P2860
P304
P356
10.1080/23723556.2017.1287554
P577
2017-02-03T00:00:00Z